Related Experiment Video
Updated: Dec 28, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer's disease mice
Neta Lax1, Nina Fainstein1, Yossi Nishri1
1Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
Background:
Accumulating data suggest a central role for brain microglia in mediating cortical neuronal death in Alzheimer's disease (AD), and for Toll-like receptor 2 (TLR2) in their toxic activation. Amyloid deposition in preclinical AD is associated with microglial activation but not directly with neurodegeneration. We examined in transgenic 5xFAD mice the hypothesis that systemic TLR2 agonists, derived from common infectious agents, may accelerate neurodegeneration in AD.
Methods:
Microbial wall-derived TLR2 agonists zymosan and lipoteichoic acid were administered intraperitoneally or intracerebroventricularly to 7-month-old wild-type or 5xFAD mice. Immunofluorescent stainings were used to quantify cortical neurons and evaluate tissue reaction. Microglial activation was assessed using functional assays, RNA expression, and FACS analysis.
Results:
Repeated low-dose systemic administration of zymosan or lipoteichoic acid killed cortical neurons in 5xFAD mice but not in wild-type mice. Direct CNS delivery of a selective TLR2 antagonist blocked the neurotoxicity of systemically administered zymosan, indicating that CNS TLR2 mediates this effect. Systemically administered zymosan crossed the disrupted blood-brain barrier in 5xFAD mice and entered brain parenchyma. By intracerebroventricular delivery, we found a dose- and exposure time-dependent acute neurotoxic effect of the microbial TLR2 agonist, killing cortical neurons. 5xFAD mice exhibited significantly increased vulnerability to TLR2 agonist-induced neuronal loss as compared to wild-type mice. Microbial TLR2-induced neurodegeneration was abolished by inhibiting microglia. The vulnerability of 5xFAD mice brains was mediated by an increase in number and neurotoxic phenotype of TLR2-expressing microglia.
Conclusions:
We suggest that repeated exposure to microbial TLR2 agonists may facilitate neurodegeneration in AD by their microglial-mediated toxicity to the hyper-vulnerable environment of the AD brain.
Insights
Systemic exposure to microbial Toll-like receptor 2 (TLR2) agonists accelerates neurodegeneration in Alzheimer's disease (AD) mouse models. This occurs via microglial activation within the AD brain, highlighting a potential mechanism for disease progression.
Area of Science:
- Neuroscience
- Immunology
- Alzheimer's Disease Research
Background:
- Microglia play a key role in cortical neuron death in Alzheimer's disease (AD).
- Toll-like receptor 2 (TLR2) activation in microglia is implicated in neurotoxicity.
- Amyloid deposition in preclinical AD correlates with microglial activation but not direct neurodegeneration.
Purpose of the Study:
- To investigate if systemic Toll-like receptor 2 (TLR2) agonists accelerate neurodegeneration in AD.
- To examine the role of microglia and TLR2 in mediating neurotoxicity in a transgenic AD mouse model (5xFAD).
Main Methods:
- Administration of TLR2 agonists (zymosan, lipoteichoic acid) to wild-type and 5xFAD mice.
- Evaluation of cortical neuron survival, microglial activation, and blood-brain barrier integrity.
- Assessment of neurotoxicity through direct central nervous system (CNS) delivery of TLR2 agonists and antagonists.
Main Results:
- Systemic TLR2 agonists caused cortical neuron death in 5xFAD mice but not wild-type mice.
- TLR2 agonists crossed the disrupted blood-brain barrier in 5xFAD mice, with CNS TLR2 mediating the neurotoxicity.
- 5xFAD mice showed increased vulnerability due to a higher number of neurotoxic, TLR2-expressing microglia.
Conclusions:
- Repeated exposure to microbial TLR2 agonists may exacerbate neurodegeneration in AD.
- Microglial-mediated toxicity, triggered by TLR2 agonists, contributes to neuronal loss in the AD brain environment.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

